sourcing the best research evidence in ophthalmology

Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery (COMPASS)

May 13, 2021

Safety and Effectiveness of CyPass Supraciliary Micro-Stent in Primary Open-Angle Glaucoma: 5-Year Results from the COMPASS XT Study.

Reiss G, Clifford B, Vold S, He J, Hamilton C, Dickerson J, Lane S.

Am J Ophthalmol. 2019 Dec;208:219-225.
Full text | Metrics.

Main finding: Few sight-threatening serious ocular adverse events occurred following Micro-Stent implantation, and clinical evidence of corneal decompensation was minimal

Purpose: To evaluate the safety and efficacy of insertion of the CyPass microstent in patients with mild-moderate POAG undergoing cataract surgery.
Study type: Safety extension of Randomized controlled trial
Condition: Primary Open angle glaucoma

Participants: ≥45 yo, mild-moderate POAG + clinically significant cataract, medicated IOP ≤25 or unmedicated IOP 21-33mmHg

n=505

Intervention:

Group 1: Phacoemulsification
Group 2: Phacoemulsification + Cypass microstent

A higher proportion of subjects in the Micro-Stent group was able to achieve a reduction of ≥20% in intraocular pressure without using hypotensive medication than in the control group (46% VS 32.1%)

Changes in mean BCVA from baseline, clinical examinations, pachymetry, and VF mean deviation were similar in the 2 groups.

Corneal Endothelial Cell Loss and Morphometric Changes 5 Years after Phacoemulsification with or without CyPass Micro-Stent.

Lass JH, Benetz BA, He J, Hamilton C, Von Tress M, Dickerson J, Lane S.

Am J Ophthalmol. 2019 Dec;208:211-218.
Full text | Metrics.

Main finding: In eyes with Open Angle Glaucoma, endothelial cell loss (ECL) after phacoemulsification is acute and stabilizes after 3 months, whereas ECL after phacoemulsification plus Micro-Stent implantation proceeds for at least 5 years.

Purpose: To evaluate long-term changes in corneal endothelial cells after phacoemulsification with or without supraciliary Micro-Stent in eyes with open-angle glaucoma and visually significant cataract.
Study type: Safety extension of Randomized controlled trial
Condition: Primary Open angle glaucoma

Participants: ≥45 yo, mild-moderate POAG + clinically significant cataract, medicated IOP ≤25 or unmedicated IOP 21-33mmHg

n=505

Intervention:

Group 1: Phacoemulsification
Group 2: Phacoemulsification + Cypass microstent

At 48 and 60 months, endothelial cell loss was greater in the Micro-Stent group than in the control group (-20.4% VS -10.1% at month 60)

Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts.

Vold S, Ahmed II, Craven ER, Mattox C, Stamper R, Packer M, Brown RH, Ianchulev T.

Ophthalmology. 2016 Oct;123(10):2103-12.
Full text | Metrics.

Main finding: There was early and sustained IOP reduction and glaucoma medication use after insertion of the CyPass microstent in patients with mild-to-moderate POAG.

Purpose: To evaluate the safety and efficacy of insertion of the CyPass microstent in patients with mild-moderate POAG undergoing cataract surgery.
Study type: Randomized controlled trial
Condition: Primary Open angle glaucoma

Participants: ≥45 yo, mild-moderate POAG + clinically significant cataract, medicated IOP ≤25 or unmedicated IOP 21-33mmHg

n=505

Intervention:

Group 1: Phacoemulsification
Group 2: Phacoemulsification + Cypass microstent

Share This Article :

Updated on March 7th, 2022

Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery (COMPASS)

Source Archive